Glenmark Pharmaceuticals
750 Corporate Drive
Mahwah
NJ
07430
United States
Tel: 201-684-8000
Website: https://glenmarkpharma-us.com/
115 articles about Glenmark Pharmaceuticals
-
Glenmark said it should be able to resolve the FDA's concerns within six to nine weeks and will work with the regulatory agency toward approval.
-
Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years
5/8/2019
The study of Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg] nasal spray) in pediatric patients aged 6 to under 12 years of age met its primary endpoint, and results were consistent with extensive clinical trial experience with Ryaltris in patients 12 years of age and older
-
1Q2019 Life Science Growth Announcements
4/18/2019
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry. -
BioSpace Movers and Shakers: March 8
3/8/2019
Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family. -
Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.
-
Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company
3/5/2019
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that Alessandro Riva, MD, will join its new innovation company as Chief Executive Officer.
-
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting
3/1/2019
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the presentation of a new post hoc analysis of data from a Phase 2a, proof-of-concept study of GBR 830 at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
-
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
2/25/2019
Glenmark Pharmaceuticals, a global innovative pharmaceutical company, today announced results from new analyses of pooled data from clinical studies of Ryaltris
-
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
2/19/2019
Ryaltris also known as GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration as a treatment of seasonal allergic rhinitis in patients 12 years and older
-
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a standalone company based in the United States. The new business will have its own chief executive officer and board of directors.
-
Glenmark to spin off its innovation business into a new company in the US
2/14/2019
The new innovation company will house the current innovative pipeline of 8 assets (NBEs & NCEs), which includes 5 clinical and 3 pre-clinical assets; and innovation-related R&D centres, manufacturing infrastructure and technology.
-
Glenmark Pharmaceuticals Announces Entry into Branded Dermatology Segment in the United States
12/18/2018
Glenmark's branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA
-
Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018
12/14/2018
Glenmark Pharmaceuticals, a global innovative pharmaceutical company, today announced the presentation of new pharmacokinetic data from the ongoing Phase 1 trial of GBR 1302, a HER2xCD3 bispecific antibody, at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2018 in Geneva, Switzerland
-
Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris™ at the ACAAI Annual Scientific Meeting 2018
11/15/2018
Ryaltris, formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset
-
Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
11/7/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the decision to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342.
-
Glenmark Pharmaceuticals Celebrates the Inauguration of its U.S. Manufacturing Site in Monroe, North Carolina
10/30/2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the official inauguration of its manufacturing site in Monroe, North Carolina.
-
Glenmark Pharmaceuticals Celebrates Inauguration of $100 Million Facility in Monroe, N.C.
10/25/2018
Glenmark Pharmaceutical will hold an inauguration ceremony of its manufacturing facility built in Monroe, N.C. on Tuesday, October 30, at 10:30 a.m.
-
Data on Glenmark Pharmaceuticals' GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference
10/18/2018
Glenmark Pharmaceuticals will be presented at the Fall Clinical Dermatology Conference in Las Vegas.
-
Mitra Biotech Announces Partnership with Glenmark Pharmaceuticals to Provide Clinically Relevant Translational Platform Supporting Development of Immuno-Oncology Portfolio
9/12/2018
Mitra Biotech today announced a partnership with Glenmark Pharmaceuticals focused on advancing Glenmark's proprietary immuno-oncology drug pipeline.
-
Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.